 WATERTOWN, Mass., Sept. 17, 2021 GLOBE NEWSWIRE -- EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT, a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that a late-breaking abstract highlighting topline data for the Phase 1 DAVIO trial of EYP-1901 in wet AMD has been selected for presentation at the American Academy of Ophthalmology AAO 2021 Annual Meeting to be held from November 12 15, 2021. 